

## FITC anti-mouse/human CD45R/B220 Antibody

<b>Catalog# / Size</b>	103205 / 50 µg 103206 / 500 µg
<b>Clone</b>	RA3-6B2
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	B220
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL- <i>Fas<sup>lpr</sup></i> and MRL- <i>Fas<sup>gld</sup></i> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

### Product Details

<b>Verified Reactivity</b>	Mouse, Human
<b>Reported Reactivity</b>	Cat
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Abelson murine leukemia virus-induced pre-B tumor cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm)
<b>Application Notes</b>	Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1</sup> , <i>in vitro</i> and <i>in vivo</i> modulation of B cell responses <sup>2-4</sup> , immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections <sup>5,6</sup> , and spatial biology (IBEX) <sup>14,15</sup> .
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Coffman RL. 1982. <i>Immunol. Rev.</i> 69:5. (IP)</li> <li>2. George A, et al. 1994. <i>J. Immunol.</i> 152:1014. (Activ)</li> <li>3. Asensi V, et al. 1989. <i>Immunology</i> 68:204. (Activ)</li> <li>4. Domiati-Saad R, et al. 1993. <i>J. Immunol.</i> 151:5936. (Activ)</li> <li>5. Hata H, et al. 2004. <i>J. Clin. Invest.</i> 114:582. (IHC)</li> <li>6. Monteith CE, et al. 1996. <i>Can. J. Vet. Res.</i> 60:193. (IHC)</li> <li>7. Shih FF, et al. 2006. <i>J. Immunol.</i> 176:3438. (FC)</li> </ol>

8. Chang C L-T, *et al.* 2007. *J. Immunol.* 178:6984.
9. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)
14. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
15. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Lunardi A, *et al.* 2015. *Cancer Discovery.* 5:550. [PubMed](#)
2. Zaman R, *et al.* 2021. *Immunity.* .: [PubMed](#)
3. Katsumura KR, *et al.* 2018. *Proc Natl Acad Sci U S A.* 115:E10109. [PubMed](#)
4. Shah D, *et al.* 2021. *Oncoimmunology.* 10:1939601. [PubMed](#)
5. Zhao J, *et al.* 2021. *Emerg Microbes Infect.* 10:913. [PubMed](#)
6. Lutter K, *et al.* 2022. *Front Immunol.* 13:967914. [PubMed](#)
7. Bruggemann TR, *et al.* 2022. *iScience.* 25:105185. [PubMed](#)
8. Israelow B, *et al.* 2020. *bioRxiv.* . [PubMed](#)
9. Furuta Y, *et al.* 2017. *PLoS One.* 12(2):e0172509. [PubMed](#)
10. Hata E, *et al.* 2016. *Int Immunol.* 28: 283 - 292. [PubMed](#)
11. Engel O, *et al.* 2015. *Stroke.* 46: 3232 - 3240. [PubMed](#)
12. Kaku H, *et al.* 2014. *J Immunol.* 193:5904. [PubMed](#)
13. Wu N, *et al.* 2020. *Cell Rep.* 30:1129. [PubMed](#)
14. Schönberger K, *et al.* 2022. *Cell Stem Cell.* 29:131. [PubMed](#)
15. Zhang R, *et al.* 2021. *Cell Mol Immunol.* 18:1222. [PubMed](#)
16. Ota T, *et al.* 2013. *J Immunol.* 191:3179. [PubMed](#)
17. Xia S, *et al.* 2014. *J Leukoc Biol.* 95:733. [PubMed](#)
18. Tan X, *et al.* 2016. *PLoS One.* 11: 0160985. [PubMed](#)
19. Bao H, *et al.* 2020. *Mol Med Rep.* 4.675. [PubMed](#)
20. Dong L, *et al.* 2021. *Cancer Cell.* . [PubMed](#)
21. Stewart I *et al.* 2018. *Immunity.* 49(3):477-489 . [PubMed](#)
22. Kim CJ, *et al.* 2018. *Immunity.* 49:1034. [PubMed](#)
23. Kelly L, *et al.* 2011. *J Immunol.* 187:3026. [PubMed](#)
24. Hewitson JP, *et al.* 2020. *J Immunol.* 204:2949. [PubMed](#)
25. Johnson KD, *et al.* 2022. *Blood Adv.* 6:1464. [PubMed](#)
26. Chen X, *et al.* 2021. *Theranostics.* 11:4655. [PubMed](#)
27. Zhu X, *et al.* 2017. *Arch Oral Biol.* 10.1016/j.archoralbio.2017.03.010. [PubMed](#)
28. Jones M, *et al.* 2016. *PLoS One.* 11: 0157271. [PubMed](#)
29. Wang X, *et al.* 2016. *PLoS Pathog.* 12: 1005367. [PubMed](#)
30. Yang W, *et al.* 2020. *Nat Commun.* 3.553472222. [PubMed](#)
31. Yang X, *et al.* 2020. *Blood Sci.* 2:89. [PubMed](#)
32. Ma C, *et al.* 2022. *Proc Natl Acad Sci U S A.* 119:.. [PubMed](#)
33. Carbonneau C, *et al.* 2012. *Blood.* 119:717. [PubMed](#)
34. Luff DH, *et al.* 2021. *Front Immunol.* 631271:12. [PubMed](#)
35. Ohyagi M, *et al.* 2021. *Nat Commun.* 12:7344. [PubMed](#)
36. Xu F, *et al.* 2022. *Cell Death Discov.* 8:142. [PubMed](#)
37. Tu X, *et al.* 2022. *Nat Commun.* 13:6977. [PubMed](#)
38. Fujikura D, *et al.* 2013. *PLoS One.* 8:e55321. [PubMed](#)
39. Delgado-Benito V *et al.* 2018. *Molecular cell.* 72(4):636-649 . [PubMed](#)
40. Zanotti KJ, *et al.* 2019. *J Immunol.* 202:1573. [PubMed](#)
41. Mariani SA, *et al.* 2019. *Immunity.* 50:1439. [PubMed](#)
42. Dey A *et al.* 2019. *The EMBO journal.* 38(7) pii: e100293. [PubMed](#)
43. Huang L, *et al.* 2017. *PLoS Biol.* 10.1371/journal.pbio.2001750. [PubMed](#)
44. Dai B, *et al.* 2022. *Theranostics.* 12:7603. [PubMed](#)
45. Tanaka Y, *et al.* 2021. *Int J Mol Sci.* 22:.. [PubMed](#)
46. Ma Y, *et al.* 2015. *J Immunol.* 195: 3769 - 3780. [PubMed](#)
47. Wong R, *et al.* 2020. *Immunity.* 53(5):1078-1094.e7. [PubMed](#)
48. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
49. Qi X, *et al.* 2019. *Nat Med.* 25:1225. [PubMed](#)
50. Nakata T, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:28930. [PubMed](#)
51. Yang K, *et al.* 2022. *J Clin Invest.* 132:.. [PubMed](#)
52. Jing L, *et al.* 2022. *Front Immunol.* 13:864995. [PubMed](#)
53. Wang Z, *et al.* 2021. *J Virol.* 95:e0141421. [PubMed](#)
54. Zhang X, *et al.* 2021. *Front Immunol.* 12:680068. [PubMed](#)
55. Köchl R, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
56. Pang D, *et al.* 2015. *Clin Transl Immunology.* 4: e41. [PubMed](#)
57. Park HB, *et al.* 2020. *Oncoimmunology.* 9:1772663. [PubMed](#)
58. Wang GZ, *et al.* 2019. *Nat Commun.* 10:1125. [PubMed](#)
59. Mrdjen D *et al.* 2018. *Immunity.* 48(2):380-395 . [PubMed](#)
60. Zhang L, *et al.* 2021. *Methods Mol Biol.* 2388:175. [PubMed](#)
61. Yang L, *et al.* 2021. *Cell Death Differ.* 28:2616. [PubMed](#)
62. Nabar NR, *et al.* 2022. *Autophagy.* 18:204. [PubMed](#)
63. Zhang B, *et al.* 2021. *Nat Biomed Eng.* 5:1288. [PubMed](#)
64. Lu X, *et al.* 2016. *Nat Commun.* 7: 12719. [PubMed](#)
65. Hrdinka M, *et al.* 2016. *PLoS One.* 11: 0162863. [PubMed](#)
66. Li Y, *et al.* 2020. *Cell Stem Cell.* 27(5):732-747.e7. [PubMed](#)
67. DeVito NC, *et al.* 2021. *Cell Reports.* 35(5):109071. [PubMed](#)
68. Noah AC, *et al.* 2020. *J Appl Physiol* (1985). 473:128. [PubMed](#)
69. Derecka M, *et al.* 2020. *Nat Immunol.* 261:21. [PubMed](#)

70. Hutter K, *et al.* 2020. FEBS J. . [PubMed](#)
71. Greenwald AC, *et al.* 2019. J Exp Med. 216:215. [PubMed](#)
72. Srivastava S, *et al.* 2019. Cancer Cell. 35:489. [PubMed](#)
73. Paul S, *et al.* 2018. Appl Microbiol Biotechnol. 102:8895. [PubMed](#)
74. Marinescu CI, *et al.* 2021. Stem Cell Res Ther. 12:319. [PubMed](#)
75. Zhu Y, *et al.* 2022. Clin Transl Med. 12:e887. [PubMed](#)
76. Elahi S, *et al.* 2020. Stem Cell Res. 43:101710. [PubMed](#)
77. Zhang YN, *et al.* 2020. EBioMedicine. 56:102819. [PubMed](#)
78. Siamishi I, *et al.* 2020. Cell Reports. 31(11):107756. [PubMed](#)
79. St Clair JB, *et al.* 2017. PLoS One. 12:e0170556. [PubMed](#)
80. Roy K, *et al.* 2019. Immunity. 50:616. [PubMed](#)
81. Garo LP, *et al.* 2019. Cell Rep. 28:3353. [PubMed](#)
82. Reismann D, *et al.* 2017. Nat Commun. 10.1038/s41467-017-01538-9. [PubMed](#)
83. Chen X, *et al.* 2021. Cell Rep. 37:109991. [PubMed](#)
84. Ku C, *et al.* 2015. Genes Dev. 29: 1930-1941. [PubMed](#)
85. Lim CX, *et al.* 2020. Cell Rep. 3793:30. [PubMed](#)
86. Xiang W, *et al.* 2018. Nat Commun. 9:2574. [PubMed](#)
87. Zhang H, *et al.* 2019. Mol Cell. 76:110. [PubMed](#)
88. Li H, *et al.* 2020. Nature. 584:274. [PubMed](#)
89. Gu X, *et al.* 2022. Vaccines (Basel). 10:. [PubMed](#)
90. Kondo M, *et al.* 2016. J Immunol. 196: 563 - 572. [PubMed](#)
91. Hayashi K, *et al.* 2015. Int Immunol. 27: 435-445. [PubMed](#)
92. Morrison V, *et al.* 2015. J Immunol. 195: 105 - 115. [PubMed](#)
93. Jamali A, *et al.* 2020. Cell Reports. 32(9):108099. [PubMed](#)
94. Wittner J, *et al.* 2022. Mucosal Immunol. 15:668. [PubMed](#)
95. Kang X, *et al.* 2022. J Immunol Res. 2022:8118577. [PubMed](#)
96. Georgoudaki A, *et al.* 2016. Cell Rep. 15: 2000-2011. [PubMed](#)
97. Liu R, *et al.* 2018. Front Immunol. 9:592. [PubMed](#)
98. Nowlan B, *et al.* 2019. Haematologica. 105:71. [PubMed](#)
99. Morelli AE, *et al.* 2020. Cell Rep. 30:3448. [PubMed](#)
100. Zhang W, *et al.* 2020. Nat Commun. 11:1187. [PubMed](#)
101. Liu J, *et al.* 2021. Immun Inflamm Dis. 9:299. [PubMed](#)
102. Liu R, *et al.* 2021. Mol Cell Biol. 41:e0025121. [PubMed](#)
103. Chen C, *et al.* 2021. J Virol. 95:e0082921. [PubMed](#)
104. Chen RJ, *et al.* 2022. iScience. 25:105595. [PubMed](#)
105. Chen R, *et al.* 2021. Cell Reports. 34(7):108751. [PubMed](#)
106. Hirata SI, *et al.* 2020. Allergy. 75:1939. [PubMed](#)
107. Hsieh Y, *et al.* 2014. Infect Immun. 82:2087. [PubMed](#)
108. Baomei Wang *et al.* 2019. Cell reports. 26(6):1614-1626 . [PubMed](#)
109. Weng TY, *et al.* 2018. Sci Rep. 8:8216. [PubMed](#)
110. Zhang C, *et al.* 2021. J Virol. 95:e0079021. [PubMed](#)
111. Al-Barwani F, *et al.* 2014. PLoS One. 9:104523. [PubMed](#)
112. Younes AI, *et al.* 2021. Transl Oncol. 14:100983. [PubMed](#)
113. Kobia FM, *et al.* 2020. PLoS Biol. 18:e3000850. [PubMed](#)
114. Schuler F, *et al.* 2017. Nat Commun. 10.1038/s41467-017-01850-4. [PubMed](#)
115. Laban H, *et al.* 2018. J Cell Biol. 217:1503. [PubMed](#)
116. Alexander Mildner *et al.* 2017. Immunity. 46(5):849-862 . [PubMed](#)
117. Raju S, *et al.* 2020. Cell Reports. 29(9):2556-2564.e3.. [PubMed](#)
118. Sanchez HN, *et al.* 2020. Nat Commun. 0.5. [PubMed](#)
119. Nguyen HTT, *et al.* 2021. PLoS Pathog. 17:e1010026. [PubMed](#)
120. Soria-Castro R, *et al.* 2020. Sci Rep. 10:17802. [PubMed](#)
121. Ghezraoui H, *et al.* 2018. Nature. 560:122. [PubMed](#)
122. Tian D, *et al.* 2019. Nat Commun. 10:4246. [PubMed](#)
123. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
124. Zheng Y, *et al.* 2022. J Immunol. 208:501. [PubMed](#)
125. Hoechst B, *et al.* 2016. J Immunol. 195:1517-1523. [PubMed](#)
126. Wu Y, *et al.* 2015. J Immunol. 195: 2612-2623. [PubMed](#)
127. Takahashi T, *et al.* 2017. J Exp Med. 10.1084/jem.20160247. [PubMed](#)
128. Li K, *et al.* 2020. Nat Commun. 4.8444444444. [PubMed](#)
129. Golan K *et al.* 2018. Cell stem cell. 23(4):572-585 . [PubMed](#)
130. Zegarra-Ruiz DF *et al.* 2018. Cell host & microbe. 25(1):113-127 . [PubMed](#)
131. Velazquez VM, *et al.* 2017. Mol Ther Methods Clin Dev. 0.277083333. [PubMed](#)
132. Ota T, *et al.* 2011. J Exp Med. 208:617. [PubMed](#)
133. Tsyklauri O, *et al.* 2021. EMBO Rep. 22:e50785. [PubMed](#)
134. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. [PubMed](#)
135. Srivastava S, *et al.* 2020. Cancer Cell. 39(2):193-208.e10. [PubMed](#)
136. Iwanami N, *et al.* 2020. iScience. 23:101260. [PubMed](#)
137. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
138. Burton OT, *et al.* 2018. Clin Exp Allergy. 48:288. [PubMed](#)
139. Nakamura K, *et al.* 2018. Cancer Cell. 33:634. [PubMed](#)
140. Pan J, *et al.* 2022. Front Immunol. 13:812924. [PubMed](#)
141. Ioanna E Galani *et al.* 2017. Immunity. 46(5):875-890 . [PubMed](#)
142. Jing Y, *et al.* 2019. J Allergy Clin Immunol. 144:1377. [PubMed](#)
143. Awida Z, *et al.* 2021. Int J Mol Sci. 23:. [PubMed](#)
144. Uematsu T, *et al.* 2015. Sci Rep. 5: 17577. [PubMed](#)
145. Tham SM, *et al.* 2021. Biomedicines. 9:. [PubMed](#)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	B cells, T cell subset, NK cell subset
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Cell Type</b>	B cells, NK cells, T cells
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"><li>1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li><li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li><li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li><li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li></ol>
<b>Gene ID</b>	<a href="#">19264</a> <a href="#">5788</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

Alexa Fluor® 594 anti-mouse/human CD45R/B220, APC anti-mouse/human CD45R/B220, Biotin anti-mouse/human CD45R/B220, FITC anti-mouse/human CD45R/B220, PE anti-mouse/human CD45R/B220, PE/Cyanine5 anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220, PE/Cyanine7 anti-mouse/human CD45R/B220, APC/Cyanine7 anti-mouse/human CD45R/B220, Alexa Fluor® 488 anti-mouse/human CD45R/B220, Alexa Fluor® 647 anti-mouse/human CD45R/B220, Pacific Blue™ anti-mouse/human CD45R/B220, Alexa Fluor® 700 anti-mouse/human CD45R/B220, PerCP anti-mouse/human CD45R/B220, PerCP/Cyanine5.5 anti-mouse/human CD45R/B220, Brilliant Violet 421™ anti-mouse/human CD45R/B220, Brilliant Violet 570™ anti-mouse/human CD45R/B220, Brilliant Violet 650™ anti-mouse/human CD45R/B220, Brilliant Violet 605™ anti-mouse/human CD45R/B220, Brilliant Violet 785™ anti-mouse/human CD45R/B220, Brilliant Violet 510™ anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220 (Maxpar® Ready), Brilliant Violet 711™ anti-mouse/human CD45R/B220, PE/Dazzle™ 594 anti-mouse/human CD45R/B220, APC/Fire™ 750 anti-mouse/human CD45R/B220, Brilliant Violet 750™ anti-mouse/human CD45R/B220, TotalSeq™-A0103 anti-mouse/human CD45R/B220, Spark Blue™ 550 anti-mouse/human CD45R/B220, Spark NIR™ 685 anti-mouse/human CD45R/B220, TotalSeq™-B0103 anti-mouse/human CD45R/B220, Ultra-LEAF™ Purified anti-mouse/human CD45R/B220, TotalSeq™-C0103 anti-mouse/human CD45R/B220, PE/Fire™ 640 anti-mouse/human CD45R/B220, APC/Fire™ 810 anti-mouse/human CD45R/B220, PE/Fire™ 700 anti-mouse/human CD45R/B220, Spark Violet™ 538 anti-mouse/human CD45R/B220, Spark YG™ 581 anti-mouse/human CD45R/B220, Spark YG™ 570 anti-mouse/human CD45R/B220, PE/Fire™ 810 anti-mouse/human CD45R/B220, Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody, Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody, Spark Red™ 718 anti-mouse/human CD45R/B220

## Product Data

---



C57BL/6 mouse splenocytes stained with RA3-6B2 FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587